Next-Generation Sequencing and Genotype Association Studies Reveal the Association of HLA-DRB3*02:02 With Delayed Hypersensitivity to Penicillins

Antonino Romano1, Abderrahim OUSSALAH2, Céline Chery3, Rosa Maria Rodriguez-Gueant4, Francesco Gaeta5, José Antonio Cornejo-García6, Pierre ROUYER3, Thomas Josse7, Cristobal Mayorga8, María José Torres9, and Jean Louis Gueant4

1University of Lorraine, INSERM UMRs1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine
2Faculty of Medicine of Nancy, University of Lorraine
3Inserm U 954
4University of Nancy
5Allergy Unit, Columbus Hospital, Fondazione Policlinico A. Gemelli
6Malaga Regional University Hospital-IBIMA, UMA
7Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, and Nutrition, University Hospital of Nancy
8IBIMA-Regional University Hospital of Malaga
9Universidad de Málaga Facultad de Medicina

April 16, 2021

Abstract

Background: Nonimmediate (delayed) allergic reactions to penicillins are common and some of them can be life-threatening. The genetic factors influencing these reactions are unknown/poorly known/poorly understood. We assessed the genetic predictors of a delayed penicillin allergy that cover the HLA loci. Methods: Using next-generation sequencing (NGS), we genotyped the MHC region in 24 patients with delayed hypersensitivity compared with 20 patients with documented immediate hypersensitivity to penicillins recruited in Italy. Subsequently, we analyzed in silico Illumina Immunochip genotyping data that covered the HLA loci in 98 Spanish patients with delayed hypersensitivity and 315 with immediate hypersensitivity compared to 1,308 controls. Results: The two alleles DRB3*02:02:01:02 and DRB3*02:02:01:01 were reported in twenty cases with delayed reactions (83%) and ten cases with immediate reactions (50%), but not in the Allele Frequency Net Database. Bearing at least one of the two alleles increased the risk of delayed reactions compared to immediate reactions, with an OR of 8.88 (95% CI, 3.37–23.32; P <0.0001). The haplotype (ACAA) from rs9268835, rs6923504, rs6903608, and rs9268838 genetic variants of the HLA-DRB3 genomic region was significantly associated with an increased risk of delayed hypersensitivity to penicillins (OR, 1.7; 95% CI: 1.06–1.92; P=0.001), but not immediate hypersensitivity. Conclusion: We showed that the HLA-DRB3 locus is strongly associated with an increased risk of delayed penicillin hypersensitivity, at least in Southwestern Europe. The determination of HLA-DRB3*02:02 alleles in the risk management of severe delayed hypersensitivity to penicillins should be evaluated further in larger population samples of different origins.

INTRODUCTION

Penicillin “allergy” is the most common drug-class allergy identified in electronic medical records of large healthcare systems.1-3 Specifically, penicillin allergy was reported by 12.8% of the entire patient population (n
Urticaria (hives) and rash are the reactions most commonly reported by patients presenting for a penicillin allergy evaluation. In fact, natural penicillins (i.e., penicillin G and penicillin V) and aminopenicillins (i.e., ampicillin and amoxicillin) were the causative drugs counting for 100,943 (37.5%) of 269,493 “rash/dermatitis” cases and for 61,457 (40.8%) of 150,450 “hives/urticaria” instances listed in a US-based electronic-health-record analysis.

Based on their chronology, hypersensitivity reactions to penicillins are classifiable as immediate or non-immediate (also called delayed). The former occurs within 6 hours after the last drug administration, though typically within one hour after the first dose of a new treatment course. They usually manifest as isolated symptoms, such as urticaria, angioedema, bronchospasm, and hypotension, or as anaphylaxis, and are mostly associated with an IgE-mediated pathogenic mechanism. Nonimmediate reactions occur more than one hour after the initial drug administration, commonly after many days of treatment, are more frequent than immediate reactions, and are characterized by a wide range of clinical manifestations, including severe ones such as Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction (or rash) with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Maculopapular exanthema (MPE) and delayed-appearing urticaria are the most common clinical presentations of nonimmediate reactions. In some nonimmediate reactions, especially DRESS, AGEP, and MPE, a T-cell-mediated pathogenic mechanism has been demonstrated on the basis of positive responses to patch tests and/or delayed-reading intradermal tests.

Despite a high prevalence of nonimmediate reactions to penicillins, little is known about the influence of genetic determinants, in contrast to the pharmacogenetic data published on immediate reactions. An Italian case-control study by Romano et al. assessed the HLA-A2 and HLA-DRw52 alleles in 24 patients with MPE caused by delayed hypersensitivity to aminopenicillins compared to 522 subjects from the general population and found that they were significantly more prevalent among the former. However, it is noteworthy that no genome-wide association study (GWAS) or HLA genotyping with next-generation sequencing (NGS) has been performed to evaluate the contribution of the genetic determinants. To address this issue, we evaluated the influence of HLA genetic determinants on the risk of nonimmediate reactions to penicillins by performing HLA NGS genotyping/NGS-based HLA typing in 24 patients with delayed hypersensitivity and 20 patients with immediate hypersensitivity to penicillins recruited in Italy. Then we performed NGS-based HLA typing for a case-control study to estimate the association between the potentially enriched HLA alleles obtained and the risk of nonimmediate hypersensitivity to penicillins. We subsequently replicated the results using in silico data from the Illumina Immunochip genotyping array that covered the HLA loci in 98 Spanish patients with delayed hypersensitivity compared to 1,308 controls.

**METHODS**

**Overview of the study design**

We performed NGS-based HLA typing to assess potentially enriched HLA alleles in patients with thoroughly documented delayed hypersensitivity to penicillins. We also performed the HLA-based typing to assess the potentially enriched *HLA-DRB3* alleles in 20 patients with documented immediate hypersensitivity to penicillins. We compared the delayed-hypersensitivity cases with the immediate ones to estimate the risk of nonimmediate reactions related to *HLA-DRB3* among patients with hypersensitivity to penicillins. Finally, we replicated the results using GWAS data from our previous study of a large Spanish population. We performed per-variant and per-haplotype association studies on the haplotype and variants significantly associated with the risk of delayed hypersensitivity.

**Study sample description**

**Italian cases assessed by NGS**

A total of 24 Italian cases with T-cell-mediated hypersensitivity to penicillins and 20 with immediate hypersensitivity were studied by NGS-based HLA genotyping. The participants were recruited in the allergy units of the Columbus Hospital, Rome, Italy and Oasi Research Institute-IRCCS, Troina, Italy between January
2000 and June 2016. Participants were evaluated by skin tests and patch tests with penicillin reagents, as previously described.\textsuperscript{16,17} Skin tests and patch tests with five cephalosporins were also performed. The inclusion criterion of the 24 cases was a reported delayed reaction to penicillin and a positive patch test and/or delayed-reading skin test result to at least one penicillin reagent. The 20 cases with immediate hypersensitivity had typical clinical presentations and positive prick and/or intradermal reactions. The cases with negative cephalosporin allergy tests underwent controlled administrations of therapeutic doses of the cephalosporins concerned (\textbf{Supplemental Table 1}), as previously described.\textsuperscript{16} The 24 subjects were classified into three groups according to the results of skin testing: group A, positive to ampicillin and amoxicillin; group B, positive to benzylpenicillin, ampicillin, and amoxicillin; and group C, positive to all three penicillins and aminoccephalosporins.

\textit{Spanish cases and controls assessed by GWAS}

Spanish patients were recruited in the Allergy Service, Carlos Haya Hospital, Malaga, Spain. From the initial samples of the 436 patients and 1218 control subjects, 413 and 1124 passed quality control for HLA loci, respectively, and were retained in the final statistical analyses. We used 184 additional control subjects from the same population, which allowed us to perform the association study with 1308 controls. The retained population included 98 cases with delayed hypersensitivity to penicillins diagnosed as previously described\textsuperscript{18} and 315 cases with immediate allergic reactions from the aforementioned study.\textsuperscript{11} They ranged from 16 to 60 years old. The 1,308 controls were from Malaga and Salamanca (Spain), as previously described.\textsuperscript{11} Age- and gender-paired volunteers were recruited in preventive-care consultations. All of them tolerated amoxicillin and other penicillins on different occasions, and they had no histories of allergic, dermatological, or respiratory diseases. Subjects who had never taken penicillins and those with a C-reactive protein blood concentration higher than 5 mg/L were excluded from the control group. All patients and controls were of Caucasian origin. Before allergy tests, all subjects received information about possible related risks, and written informed consent for participating in the study and providing DNA samples was obtained from each patient or the parents of those under 18 years of age. The respective institutional review boards approved the protocol.

\textit{NGS-based HLA genotyping}

High-throughput genotyping of DNA samples was performed at the INSERM Unit UMR_S 1256 (NGERE, University of Lorraine, France) according to the manufacturer’s recommendations. We used the Illumina TruSight HLA v2 (Illumina Inc. CA, USA) sequencing panel, which provides high-resolution sequencing of 11 HLA loci (\textit{HLA-A}, \textit{HLA-B}, \textit{HLA-C}, \textit{HLA-DRB1}/3/4/5, \textit{HLA-DQB1}, \textit{HLA-DPB1}, \textit{HLA-DQA1}, and \textit{HLA-DPA1}), according to the manufacturer’s instructions at the INSERM Unit UMR_S 1256 (NGERE, University of Lorraine, France). Libraries were run in parallel on a MiSeq system (Illumina Inc. CA, USA) using 250 bp paired-end reads. We performed HLA allele assignation on the generated FASTQ files, using the TruSight HLA Assign 2.0 Software (Illumina Inc. CA, USA) to align the sequence reads and referencing with the International ImMunoGeneTics Information System/HLA database. We assessed the allele frequency of each HLA allele in the 24 patients studied. We calculated the enrichment ratio for a given HLA allele by dividing its allelic frequency found in the study population by that observed in the control population, using the Allele Frequency Net Database (www.allelefrequencies.net).\textsuperscript{19} We defined the potentially enriched HLA alleles in patients with delayed hypersensitivity to penicillins as those with a frequency in the study population of at least 20\% and an enrichment ratio >2. In the second phase of the study, we used an allelic model to estimate the odds ratio (OR) and the absolute risk difference for the association between carrying at least one \textit{DRB3*02:02} allele (\textit{DRB3*02:02:01:02} or \textit{DRB3*02:02:01:01}) and the risk of delayed hypersensitivity to penicillins. We reported the 95\% confidence interval (95\% CI) and the associated \textit{P}-values for the OR and the absolute risk difference using z-statistic and Chi-squared tests, respectively.

\textit{Haplotype analysis and genetic association study}

We used \textit{in silico} data generated from a previously reported fine-mapping GWAS on genetic predictors of penicillin allergy using the Illumina Immunochip array (Illumina Inc. CA, USA) that covers the HLA
loci. We extracted from the full dataset the genotypic data corresponding to the genetic variants located in the HLA-DRB3 locus and its vicinity. The HLA-DRB3 locus is not referenced according to the GRCh38/hg38 build, but rather according to the Homo sapiens chromosome 6 genomic contig, GRCh38 reference assembly alternate locus group ALT_REF_L0CL_20,21 with the following coordinates: hg38 chr6:GL000251v2_alt:3,934,009-3,947,126. Since the genomic positions of the Illumina ImmunoChip array were initially reported according to the NCBI36 build, we used the Liftover tool22 from the UCSC Genome Browser database to convert the genomic position of the HLA-DRB3 locus from the GRCh38 reference assembly to the NCBI36 build (chr6:32,571,675-32,584,792). Because of the complex structure and high level of linkage disequilibrium (LD) in the HLA locus,23 we considered all the genetic variants located in the intergenic region between the HLA-DRA and HLA-DRB5 genes that included the HLA-DRB3 gene. Sample quality-control measures included: sample call rate (>90%), overall heterozygosity, and relatedness testing. We assessed cryptic relatedness using identity-by-descent analysis. Genetic variants were removed from the primary analysis if they had a call rate <90%, a significant departure from Hardy-Weinberg equilibrium (exact HWE- \( P < 10^{-4} \) among controls), or a minor allele frequency <5%. We performed the genetic association analysis according to the allelic model. We completed the haplotype association analysis using a moving window with a fixed width of 4 markers. We performed LD-pairwise analysis on all adjacent pairs of genetic variants using a matrix output for both the expectation-maximization (EM) algorithm and the composite-haplotype method.24,25 We used D’ values in the LD plots. We estimated haplotype frequencies using the EM algorithm with maximum EM iterations of 50 and an EM convergence tolerance of 0.0001.26 We compared haplotype frequencies using the Chi-squared test and reported the corresponding OR, the 95% confidence interval, and the associated \( P \)-value for each haplotype. Given the exploratory nature of our analysis, we considered a genomic region as potentially relevant if it encompassed genetic variants that were significantly associated with the risk of delayed hypersensitivity to penicillins in both per-variant and per-haplotype association analyses. All statistical analyses were performed using the SNP & Variation Suite (Golden Helix, Inc., Bozeman, MT, USA).

RESULTS

HLA genotyping by NGS in cases with delayed hypersensitivity and cases with immediate hypersensitivity to penicillins

The clinical characteristics of the 24 patients with delayed hypersensitivity to penicillins who were subjected to HLA NGS/ NGS-based HLA typing are detailed in Supplemental Table 1. Taking into account the results of skin testing, subjects classified as group A (i.e., positive only to ampicillin and amoxicillin, \( n = 14 \)) were more numerous than those with less selective responses classified as group B (i.e., positive to benzylpenicillin, ampicillin and amoxicillin, \( n = 6 \)) and C (i.e., positive to penicillins and aminocephalosporins, \( n = 4 \)). On the HLA alleles retrieved in the 24 Italian patients, two HLA alleles, DRB3*02:02:01:02 and DRB3*02:02:01:01, had a dramatic enrichment among the seven alleles with an allelic frequency >20%, compared to the control population of the Allele Frequency Net Database (Table 1 and Supplemental Tables 2 and 3). The alleles DRB3*02:02:01:02 and DRB3*02:02:01:01 predicted a very high risk of delayed reaction, which could not be evaluated precisely because such alleles had not been previously reported in the general European population. 83% of the patients (20/24) harbored at least one of the two reported HLA-DRB3 alleles, and 71% (11/24) were homozygous for one of the two HLA-DRB3 alleles or had a compound heterozygous status (Table 2 and Supplemental Table 2). We observed a higher frequency of DRB3*02:02:01:02 and DRB3*02:02:01:01 homozygous genotypes in group A (n=12, 69%) than in group B and C patients (n=3, 30%). However, no difference of allele frequency was observed among the 3 groups (Table 2).

The allele frequency of the DRB3*02:02:02 alleles (DRB3*02:02:01:02 and DRB3*02:02:01:01) was significantly higher in patients with delayed hypersensitivity than in those with immediate hypersensitivity to penicillins (77% vs. 28%, respectively). These figures corresponded to an increased risk of delayed reactions in penicillin hypersensitivity cases harboring DRB3*02:02 alleles, with an OR of 8.9 (95% CI, 3.4–23.3; \( P <0.0001 \)) and an absolute risk difference of 49% (29%–64%; \( P<0.0001 \)).
Association of the HLA-DRB3 locus with delayed hypersensitivity to penicillins in the Spanish population

In order to confirm the potential enrichment in the HLA-DRB3 locus showed by the HLA NGS/NGS-based HLA typing of the 24 Italian patients, we performed a fine-mapping genetic association study to assess the per-variant and per-haplotype risk associations with genetic variants of the HLA-DRB3 genomic region in 98 Spanish patients with delayed hypersensitivity compared with 1,308 controls. The haplotype block is shown in Figure 1. We found that a haplotype (ACAA) from four genetic variants (rs9268835, rs6923504, rs6903608, and rs9268838) was significantly associated with the risk of delayed hypersensitivity to penicillins (OR, 1.7; 95% CI: 1.06–1.92; P = 0.001) (Table 3). In the per-variant analysis, two variants (rs9268835, rs9268838) of the four included in the ACAA haplotype were significantly associated with the risk of delayed hypersensitivity to penicillins, with a similar effect size (Table 4). We subsequently assessed the risk association of the ACAA haplotype in 315 patients with immediate reactions compared with 1,308 controls. The haplotype and per-variant association studies revealed no significant associations with the ACAA haplotype or with the rs9268835 and rs9268838 variants (Tables 3 and 4).

DISCUSSION

We sequenced the HLA region of 24 patients with delayed and 20 with immediate hypersensitivity to penicillins in order to analyze the risk association for all high-resolution alleles with delayed hypersensitivity. We observed a strong association of DRB3*02:02:01:02 and DRB3*02:02:01:01 alleles with the risk of penicillin delayed hypersensitivity in the 24 Italian patients. It is noteworthy that as many as 83% of the cases carried a DRB3*02:02 allele. The frequency of homozygous cases for the variants of the HLA-DRB3 locus was higher in group A (with selective hypersensitivity to ampicillin and amoxicillin) than in the less selective groups B and C, suggesting that the association reflects the specificity of hapten recognition. The association of the HLA-DRB3 locus with an increased risk of penicillin delayed hypersensitivity was confirmed by the in silico study of genetic variants of the HLA-DRB3 genomic region in Spanish patients. The protein encoded by the HLA-DRB3 gene belongs to the HLA class II beta chain paralogs, including DRB1, DRB4, and DRB5. It is part of a heterodimer consisting of an alpha chain (DRA) and a beta one (DRB) and is involved in the antigen presentation of peptides derived from extracellular proteins. The association of HLA-DRB3*02:02 with the risk of penicillin delayed hypersensitivity has never been reported for any other drug category so far. The HLA-DRB3*02:02 allele is independently and strongly associated with an increased risk of PLA2R-related idiopathic membranous nephropathy in a Chinese population. Therefore, our results suggest investigating the increased risk of delayed reactions to penicillins in this disease.

Only one study had previously evaluated the genetic determinants that contribute to the risk of delayed hypersensitivity to penicillins. This Italian case-control study assessed HLA-A2 and HLA-DRw52 alleles in 24 patients with MPE caused by delayed hypersensitivity to aminopenicillins and 522 subjects from the general population. The HLA-A2 and HLA-DRw52 alleles were significantly more prevalent among cases. However, we did not replicate this result in the NGS of the MHC region in our study. A French study assessed nine variants on genes controlling cytokine production (i.e., IL1, IL1B, IL1RN, IL2, IL4, IL5, IL10, IL16, and TNF) in 118 patients with well-defined cutaneous adverse drug reactions and 236 controls. Several responsible drugs were considered in the study, including beta-lactams. The haplotype combining IL1RN A2 and IL1B 511C alleles was associated with an increased risk of DRESS (OR = 3.22; 95% CI: 1.23-8.41). However, the number of cases was too limited to evaluate the specific risk of reactions to penicillins.

We compared our data with pharmacogenetic research on immediate penicillin allergy. Most studies have evaluated genetic determinants of immediate reactions to beta-lactams utilizing a candidate-gene approach. They found an association with genes involved in IgE production, atopy, and inflammation, including 3 genes validated by replications: ILR4, NOD2, and LGALS3. It is noteworthy that no association with HLA-DRB1*10:01, ILR4, NOD2, or LGALS3 was identified by GWAS in our patients with delayed hypersensitivity reactions to penicillins. Despite the vicinity of the HLA-DRB1/3/4/5 loci in chromosome 6, it is noteworthy that we did not find any association between the risk of delayed reactions to penicillins
and the rs7754768 and rs9268832 of the HLA-DRA | HLA-DRB5 inter-region in a GWAS performed in Italian and Spanish populations. Similarly, we found no risk association of delayed reactions with the rs71542416 within the Class II HLA region, which is associated with the risk of immediate beta-lactam allergy in GWAS performed in Italian and Spanish populations.

In conclusion, we showed that the HLA-DRB3*02:02 alleles are strongly associated with an increased risk of delayed hypersensitivity to penicillins, at least in Southwestern Europe. In regard to the severity of some of the reactions, the interest for using the determination of HLA-DRB3*02:02 alleles in the risk management of delayed hypersensitivity to penicillins should be evaluated in further studies of larger populations of different origin.

**TABLES**

**Table 1.** Frequency of the HLA alleles found in the 24 Italian patients with delayed hypersensitivity to penicillins.

<table>
<thead>
<tr>
<th>HLA allele</th>
<th>Allele frequency (study population)</th>
<th>Allele frequency (control population)*</th>
<th>Enrichment ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRB3*02:02:01:02</td>
<td>0.54</td>
<td>Absent in Europe</td>
<td>High</td>
</tr>
<tr>
<td>DRB3*02:02:01:01</td>
<td>0.23</td>
<td>Absent in Europe</td>
<td>High</td>
</tr>
<tr>
<td>DQB1*03:01:01:02</td>
<td>0.42</td>
<td>0.35</td>
<td>1.21</td>
</tr>
<tr>
<td>DPB1*04:01:01:01</td>
<td>0.42</td>
<td>0.26</td>
<td>1.60</td>
</tr>
<tr>
<td>DQA1*05:05:01:01</td>
<td>0.40</td>
<td>0.30</td>
<td>1.34</td>
</tr>
<tr>
<td>A*02:01:01:01</td>
<td>0.21</td>
<td>0.26</td>
<td>0.80</td>
</tr>
<tr>
<td>C*07:01:01:01</td>
<td>0.21</td>
<td>0.18</td>
<td>1.14</td>
</tr>
</tbody>
</table>

* We calculated the enrichment ratio for a given HLA allele by dividing its allelic frequency observed in the study population by that observed in the control population using the Allele Frequency Net Database (www.allelefrequencies.net).

**Table 2.** Distribution of the HLA DRB3*02:02 alleles in patients with delayed and those with immediate hypersensitivity to penicillins

<table>
<thead>
<tr>
<th>DRB3*02:02 alleles status</th>
<th>Delayed (n = 24)</th>
<th>Delayed (n = 24)</th>
<th>Delayed, Group A* (n = 14)</th>
<th>Delayed, Group B (n = 6)</th>
<th>Delayed, Group C (n = 4)</th>
<th>Delayed, Groups B/C (n = 10)</th>
<th>Immediate (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRB3*02:02:01:02, homozygous</td>
<td>n</td>
<td>%</td>
<td>n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRB3*02:02:01:01, homozygous</td>
<td>11</td>
<td>46%</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRB3*02:02:01:01</td>
<td>3</td>
<td>13%</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRB3<em>02:02:01:01/DRB3</em>02:02:01:02</td>
<td>3</td>
<td>13%</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRB3*02:02:01:01, heterozygous</td>
<td>2</td>
<td>8%</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRB3*02:02:01:02, heterozygous</td>
<td>1</td>
<td>4%</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No DRB3*02:02 allele</td>
<td>4</td>
<td>17%</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note. n: number of patients; %: percentage.

*Group A: reactive only to ampicillin and amoxicillin.

† Group B: reactive to benzylpenicillin, ampicillin, and amoxicillin.

‡‡Group C: reactive to both penicillins and cephalosporins.

**Table 3.** Haplotype association study for the association between HLA-DRB3 haplotypes and the risk of delayed and immediate hypersensitivity to penicillins
<table>
<thead>
<tr>
<th>Haplotype*</th>
<th>Beta-lactam hypersensitivity type</th>
<th>Odds ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACAA</td>
<td>Delayed</td>
<td>1.42 (1.06–1.92)</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>Immediate</td>
<td>1.14 (0.95–1.37)</td>
<td>0.17</td>
</tr>
<tr>
<td>GGGG</td>
<td>Delayed</td>
<td>0.79 (0.58–1.08)</td>
<td>0.14</td>
</tr>
<tr>
<td></td>
<td>Immediate</td>
<td>0.96 (0.80–1.15)</td>
<td>0.66</td>
</tr>
<tr>
<td>GCAG</td>
<td>Delayed</td>
<td>0.88 (0.64–1.21)</td>
<td>0.45</td>
</tr>
<tr>
<td></td>
<td>Immediate</td>
<td>0.92 (0.76–1.11)</td>
<td>0.36</td>
</tr>
</tbody>
</table>

Note. 95% CI: 95% confidence interval.

*HLA-DRB3* markers included in the haplotype: rs9268835, rs6923504, rs6903608, rs9268838.

**Table 4.** Genetic association study for the association between *HLA-DRB3* genetic variants and the risk of delayed and immediate hypersensitivity to penicillins

<table>
<thead>
<tr>
<th>Name</th>
<th>Risk/Ref. allele</th>
<th>Penicillin hypersensitivity type</th>
<th>Cases (n); Controls (n)</th>
<th>Call rate</th>
<th>MAF (Cases)</th>
<th>MAF (Controls)</th>
<th>Odds ratio (95% CI)</th>
<th>Fisher’s Exact P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs9268835</td>
<td>A/G</td>
<td>Delayed</td>
<td>98; 1302</td>
<td>0.986</td>
<td>0.39</td>
<td>0.31</td>
<td>1.42 (1.05–1.91)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immediate</td>
<td>315; 1302</td>
<td>0.990</td>
<td>0.34</td>
<td>0.31</td>
<td>1.14 (0.94–1.37)</td>
<td>0.18</td>
</tr>
<tr>
<td>rs6923504</td>
<td>G/C</td>
<td>Delayed</td>
<td>98; 1300</td>
<td>0.985</td>
<td>0.31</td>
<td>0.37</td>
<td>0.78 (0.57–1.06)</td>
<td>0.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immediate</td>
<td>315; 1300</td>
<td>0.990</td>
<td>0.36</td>
<td>0.37</td>
<td>0.95 (0.79–1.14)</td>
<td>0.61</td>
</tr>
<tr>
<td>rs6903608</td>
<td>G/A</td>
<td>Delayed</td>
<td>98; 1308</td>
<td>0.990</td>
<td>0.31</td>
<td>0.36</td>
<td>0.80 (0.59–1.09)</td>
<td>0.17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immediate</td>
<td>315; 1308</td>
<td>0.990</td>
<td>0.36</td>
<td>0.36</td>
<td>0.98 (0.81–1.17)</td>
<td>0.82</td>
</tr>
<tr>
<td>rs9268838</td>
<td>A/G</td>
<td>Delayed</td>
<td>98; 1303</td>
<td>0.987</td>
<td>0.39</td>
<td>0.31</td>
<td>1.43 (1.06–1.94)</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immediate</td>
<td>315; 1303</td>
<td>0.990</td>
<td>0.34</td>
<td>0.31</td>
<td>1.15 (0.95–1.38)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Note. n: number of subjects; MAF: minor allele frequency; 95% CI: 95% confidence interval.

**FIGURE LEGEND**

**Figure 1.** (A) Manhattan plot on the *HLA-DRA* | *HLA-DRB5* intergenic region, including the *HLA-DRB3* locus and its vicinity for reporting the genetic association analysis for the primary risk of nonimmediate...
reactions to penicillins, according to the allelic model. (B) Linkage disequilibrium plot illustrating the D' values between the lead variants and the other variants in the genomic region is indicated by color. The green pentagon indicates the haplotype block formed by the four variants: rs9268835, rs6923504, rs6903608, and rs9268838. (C) Genomic context of the HLA-DRA | HLA-DRB5 genomic region.

CONFLICTS OF INTEREST AND FUNDING

The authors have no conflicts of interest to declare. This work was supported by a grant from the French Ministry of Health (National Program for Clinical Research, PHRC), a “Chercheur d’excellence” grant from the Region of Lorraine (France), the research projects FHU ARRIMAGE and OMAGE from Region Grand-Est and FEDER and the French PIA project “Lorraine Université d’Excellence”, reference ANR-15-IDEX-04-LUE.

REFERENCES


Figure 1